Makes no sense. Only reason to drive price up is for uplist. Uplist won't happen until FDA guidance. FDA guidance should naturally drive price up above $2.
I wasn't a fan of buyback given concerns of FDA timing vs cash position but if they've not burned through too much cash last Q a buyback now seems reasonable. Plus I'm renewed in my hope that guidance will come soon so cash might not be as critical. Hahn has shown some initiative and Congress isn't forgetting.